M. Frank (1), A. Kunz (2), G. Harms (2), C. Kloft (1) Population pharmacokinetic model development and evaluation after nevirapine administration to mothers and newborns
|
M. Neely (1,2,3), T. Rushing (4), A. Kovacs (3), R. Jelliffe (2), J. Hoffman (1) Voriconazole Population Pharmacokinetics and Pharmacodynamics in Children
|
Jianping Zhang, Daphne D. Williams, Katy P. Moore Use of Eltrombopag Exposure-Platelet Response Relationship for Dose Optimization in Patients with Chronic HCV-Infection with and without Interferon
|
J-S van der Walt [1], K Cohen [1], HM McIlleron [1], PJ Smith [1], G Maartens [1], MO Karlsson [2] Effect of rifampicin-based antitubercular therapy and cotrimoxazole on the population pharmacokinetics of stavudine (d4T) in HIV-1 infected patients
|
A.-L. FLAUGERE(1), M. CARLES(2), E. RAMAIN (2), A. BOULAMERY-VELLY(1), N. SIMON(1) Population pharmacokinetics of imipenem bone concentrations in pigs
|
M. Lavielle (1), A. Samson (2), A.K. Fermin (3) and F. Mentré (4) Parameter estimation of long-term HIV dynamic model in the COPHAR2 – ANRS 111 trial using MONOLIX
|
C Le Guellec (1), N Simon (2), D.Garot (3), R. Respaud (1), P Lanotte (4), H. Blasco (1), PF Dequin (3). Population pharmacokinetics of Ceftriaxone in intensive care unit (ICU) adult patients
|
Ann K. Miller (1), Mita M. Thapar (2), Siobhan C. Hayes (2), Colm Farrell (2), Bela R. Patel (1), Duane A. Boyle (1) Population pharmacokinetics of artesunate and dihydroartesunate in adults and children following administration of a fixed dose combination formulation of chlorproguanil-dapsone-artesunate
|
C. Csajka (1,4), A. Pascual (2) , S. Bolay (2), J. Bille (3), T. Calandra (2), O. Marchetti (2), T. Buclin (1) Population pharmacokinetics of voriconazole in patients with invasive mycoses
|
Maria C. Kjellsson(1), Steven Kern(1,2), Robert Sauermann(3), Veronique Dartois (4), Goonaseelan (Colin) Pillai(1) Modeling the permeability of Fosfomycin into Abscess Fluid
|
W Smythe, H McIlleron, P Smith and USH Simonsson Mechanistic pharmacokinetic enzyme model for the characterisation of rifampicin pharmacokinetics in South African pulmonary TB infected adults
|
S. Rezaee(1), T. Safarnavadeh(2), H. Khalili(2), S. Dashti(2), K. Daneshjoo(3), S. Sadray(4) Population Pharmacokinetics of Vancomycin in Iranian Paediatric Patients
|
D. Santos Buelga (1), E. López (2), S. Cabrera (3), R. López (4), E. Ribera (5), A. Domínguez-Gil (1,2), M.J. García (1). Population Pharmacokinetics of Lopinavir (Kaletra) in HIV-Infected Patients
|
A. Mohamed (1), E.I. Nielsen (1), O. Cars(2) and L.E. Friberg(1). Pharmacokinetic/Pharmacodynamic Modeling of Adaptive Resistance of Gentamicin
|
A. Martin-Suarez (1), D. Santos Buelga (1), E. Lopez (2), S. Cabrera (3), R. Lopez (4), E. Ribera (5), A. Dominguez-Gil (1,2), M.J. Garcia (1). Population pharmacokinetic model for Ritonavir (RTV) in HIV-infected patients treated with Lopinavir (LPV)/RTV (KaletraTM)
|
S. Smirnov(1), A. Belashov(2), O. Demin(3) Application of pharmacokinetic-pharmacodynamic model to optimize dosing regime of antimicrobial drug Grammidin containing gramicidin S
|